Eisai’s US chair, global Alzheimer’s leader to retire weeks after Leqembi approval

Ivan Che­ung, the glob­al leader of Ei­sai’s Alzheimer’s ap­pa­ra­tus, will re­tire at the end of Ju­ly, the Japan­ese drug­mak­er said Tues­day, just four days af­ter the biotech and its part­ner Bio­gen se­cured full ap­proval for Leqem­bi.

Tak­ing his place is Ei­sai CEO Haruo Naito’s son Keisuke Naito, who will add the act­ing glob­al Alzheimer’s post to his ex­ist­ing du­ties as chief strat­e­gy and plan­ning of­fi­cer and chief ecosys­tem of­fi­cer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN